JP Morgan Chase’s Altimmune ALT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
– Sell
-100
Closed -$387 – 7369
2025
Q2
$387 Buy
+100
New +$541 ﹤0.01% 6719
2022
Q4
– Sell
-83,100
Closed -$1.06M – 6514
2022
Q3
$1.06M Buy
+83,100
New +$1.23M ﹤0.01% 3944

Other funds holding ALT

JP Morgan Chase's ALT Position: Q3 2026 in Review

JP Morgan Chase increased its Altimmune (ALT) stake by 6.7% in Q3 2026, buying an estimated $22K and bringing the position to 113,791 shares worth $338K. The position accounts for ﹤0.01% of the portfolio, ranked #5447.

JP Morgan Chase first reported a position in ALT in Q4 2016 and has held it in 29 quarters since. The position peaked at $8.31M in Q3 2022. 191 funds tracked by Wall St. Rank hold ALT as of Q3 2026.

  • JP Morgan Chase held 113,791 shares of Altimmune worth $338K as of Q3 2026.
  • JP Morgan Chase bought 7,166 Altimmune shares in Q3 2026, an estimated $22K.
  • Altimmune made up ﹤0.01% of JP Morgan Chase's portfolio in Q3 2026, its #5447 holding.
  • JP Morgan Chase first reported a position in Altimmune in Q4 2016 and has held it in 29 quarters since.
  • JP Morgan Chase's Altimmune position peaked at $8.31M in Q3 2022.
  • 191 funds tracked by Wall St. Rank held Altimmune as of Q3 2026.

Based on JP Morgan Chase's 13F filing for Q3 2026, filed 12 Nov 2026.